AlloVir (ALVR) Competitors $9.40 +0.02 (+0.16%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALVR vs. NLTX, PRQR, HURA, ZNTL, IKT, SCPH, CRDF, CGEN, SLN, and CYBNShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Neoleukin Therapeutics (NLTX), ProQR Therapeutics (PRQR), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Inhibikase Therapeutics (IKT), scPharmaceuticals (SCPH), Cardiff Oncology (CRDF), Compugen (CGEN), Silence Therapeutics (SLN), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Neoleukin Therapeutics ProQR Therapeutics TuHURA Biosciences Zentalis Pharmaceuticals Inhibikase Therapeutics scPharmaceuticals Cardiff Oncology Compugen Silence Therapeutics Cybin Neoleukin Therapeutics (NASDAQ:NLTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has higher valuation and earnings, NLTX or ALVR? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.34AlloVirN/AN/A-$190.42M-$20.23-0.46 Does the media prefer NLTX or ALVR? In the previous week, AlloVir had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for AlloVir and 1 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat AlloVir's score of -0.11 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neoleukin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AlloVir 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor NLTX or ALVR? Neoleukin Therapeutics received 23 more outperform votes than AlloVir when rated by MarketBeat users. However, 57.45% of users gave AlloVir an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% AlloVirOutperform Votes2757.45% Underperform Votes2042.55% Which has more volatility & risk, NLTX or ALVR? Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Is NLTX or ALVR more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% AlloVir N/A -71.03%-61.27% Do institutionals & insiders hold more shares of NLTX or ALVR? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryNeoleukin Therapeutics beats AlloVir on 7 of the 12 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.18M$3.00B$5.39B$9.13BDividend YieldN/A1.89%5.37%4.00%P/E Ratio-0.4646.0188.8317.53Price / SalesN/A351.371,280.48134.21Price / CashN/A189.5236.6032.90Price / Book0.324.004.964.69Net Income-$190.42M-$40.99M$117.89M$224.57M7 Day Performance7.01%1.43%1.67%1.69%1 Month Performance0.95%0.60%3.62%5.34%1 Year Performance-40.03%-2.02%26.15%21.47% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVir1.5957 of 5 stars$9.40+0.2%N/A-40.0%$47.01MN/A-0.46110Stock SplitGap DownNLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-44.8%$184.01MN/A-6.3090High Trading VolumePRQRProQR Therapeutics3.4531 of 5 stars$2.25-7.0%$8.83+292.6%+7.2%$183.78M$17.88M-7.03180Analyst RevisionNews CoveragePositive NewsGap UpHURATuHURA BiosciencesN/A$4.31-11.1%$13.00+201.6%N/A$182.25MN/A0.00N/APositive NewsZNTLZentalis Pharmaceuticals2.856 of 5 stars$2.55-7.3%$10.00+292.2%-82.5%$181.73M$40.56M-1.02160IKTInhibikase Therapeutics1.1528 of 5 stars$2.70-8.5%$6.50+140.7%+63.4%$181.42M$260,000.00-1.016News CoveragePositive NewsGap DownSCPHscPharmaceuticals3.3163 of 5 stars$3.56+4.7%$15.00+321.3%-39.3%$178.14M$30.28M-1.8730CRDFCardiff Oncology2.0881 of 5 stars$3.48-3.6%$10.33+196.9%+133.1%$177.95M$688,000.00-3.7020Positive NewsCGENCompugen2.2194 of 5 stars$1.99+21.0%$4.00+101.5%+17.0%$177.14M$59.85M99.2570High Trading VolumeSLNSilence Therapeutics2.0643 of 5 stars$5.90-1.5%$57.20+869.5%-69.8%$176.58M$16.25M-3.76100CYBNCybin2.762 of 5 stars$8.79-1.1%$138.00+1,470.0%N/A$175.73MN/A-1.3250News CoveragePositive News Related Companies and Tools Related Companies NLTX Alternatives PRQR Alternatives HURA Alternatives ZNTL Alternatives IKT Alternatives SCPH Alternatives CRDF Alternatives CGEN Alternatives SLN Alternatives CYBN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALVR) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVR Stock Alerts